Overview

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic, relapsing inflammatory disorders of the gastrointestinal tract. They represent complex conditions with variable clinical presentation, disease course, and extraintestinal manifestations.

IBD is often difficult to diagnose early due to nonspecific symptoms and overlapping features with other gastrointestinal disorders, frequently resulting in delayed diagnosis and disease progression.

In many developing healthcare systems, including Azerbaijan, limited access to specialized gastroenterology centers, diagnostic infrastructure constraints, and gaps in clinical experience contribute to prolonged diagnostic pathways and delayed treatment initiation, negatively affecting patient outcomes and quality of life.

Importance of Specialized Care

IBD requires a structured, multidisciplinary, and long-term management approach involving gastroenterologists, radiologists, pathologists, and colorectal surgeons.

In Germany, IBD care is based on evidence-driven, individualized treatment strategies, incorporating advanced endoscopic techniques, cross-sectional imaging, and immunological and biological therapies.

Within the INDID Telemedicine framework, German expertise is integrated into clinical collaboration with local physicians in Azerbaijan, supporting improved diagnostic accuracy, early disease recognition, and optimized treatment strategies.

This collaboration also represents an opportunity to strengthen medical education and clinical capacity in Azerbaijan through knowledge transfer and structured training initiatives.

Initial Diagnostic Workup and Disease Assessment

IBD diagnosis is often delayed in international settings. The INDID Telemedicine system enables structured diagnostic completion locally, without immediate need for travel to Germany.

Baseline clinical assessment

• Detailed medical history (symptom duration, stool pattern, weight loss, bleeding) 
• Family history of IBD or autoimmune disease 
• Physical examination including abdominal and perianal evaluation 
• Laboratory tests: full blood count, CRP, liver and renal function, electrolytes 

Endoscopic evaluation

• Colonoscopy with ileoscopy is the diagnostic gold standard 
• Biopsies from affected and non-affected segments are essential 
• Histological assessment confirms inflammatory pattern and disease type 
• All endoscopic and pathology reports are centrally reviewed. In cases of uncertainty or inadequate sampling, repeat evaluation or expert reassessment in German reference centers may be recommended.

Imaging

• MRI enterography (preferred for small bowel Crohn’s disease) 
• CT abdomen in acute or emergency settings 
• Ultrasound (useful for bowel wall assessment in experienced hands) 
• Perianal MRI in suspected fistulizing disease 

High-quality imaging is essential for accurate disease classification and monitoring. INDID Telemedicine supports standardized imaging protocols and quality review.

Additional diagnostic tools

• Fecal calprotectin (non-invasive inflammatory marker) 
• Stool cultures to exclude infectious causes 
• Serologic markers in selected cases (supportive, not diagnostic) 

Multidisciplinary Disease Classification and Treatment Planning

All cases are reviewed in multidisciplinary gastroenterology–surgery–radiology–pathology boards within INDID Telemedicine partner centers in Germany.

Treatment decisions are based on:

• Disease type (Crohn’s disease vs ulcerative colitis) 
• Disease extent and severity 
• Presence of complications (strictures, fistulas, abscesses) 
• Response to previous therapies 
• Nutritional and systemic status 

Treatment Modalities

Medical Therapy

Medical treatment is the foundation of IBD management and is individualized according to disease severity.

• Aminosalicylates (5-ASA) for mild to moderate ulcerative colitis 
• Corticosteroids for acute flare control (short-term use only) 
• Immunomodulators (azathioprine, methotrexate) for maintenance therapy 
• Biological therapies: 
• Anti-TNF agents 
• Anti-integrin therapies 
• IL-12/23 inhibitors 
• Small molecules (JAK inhibitors) in selected moderate-to-severe cases 

Treatment selection is guided by disease phenotype, severity, and prior response.

Surgical Treatment

Surgery is indicated in:

• Complicated Crohn’s disease (strictures, fistulas, abscesses) 
• Refractory ulcerative colitis 
• Dysplasia or malignancy risk 

Procedures include:

• Segmental bowel resection (Crohn’s disease) 
• Colectomy (ulcerative colitis) 
• Minimally invasive and organ-preserving approaches when feasible 

Surgery is integrated into a stepwise multidisciplinary treatment strategy rather than being a last resort.

Advanced and Supportive Care

• Nutritional support (especially in malabsorption or severe disease) 
• Management of anemia and micronutrient deficiencies 
• Psychological support due to chronic disease burden 
• Perianal disease management (drainage, seton placement, biologics) 

Follow-Up Strategy

IBD requires lifelong monitoring due to its chronic and relapsing nature.

Standard follow-up approach

• Regular clinical assessment every 3–6 months depending on disease activity 
• Laboratory monitoring (CRP, blood count, liver function) 
• Fecal calprotectin for disease activity assessment 
• Periodic colonoscopy for disease evaluation and dysplasia screening 
• MRI or ultrasound for small bowel or perianal disease monitoring 

Follow-up intensity is individualized based on disease severity and treatment response.

Telemedicine Follow-Up (INDID)

Patients managed through INDID Telemedicine benefit from:

• Remote monitoring of disease activity 
• Interpretation of imaging and endoscopy by German specialists 
• Treatment optimization in collaboration with local physicians 
• Long-term disease surveillance and flare prevention strategies 
• This model reduces delays in escalation of therapy and improves continuity of care.

Capacity Building and Research Initiative (Azerbaijan–Germany Collaboration)

As part of the INDID initiative:

• Regular educational seminars and training programs are being developed for general practitioners and surgeons in Azerbaijan 
• Training focuses on early recognition, diagnostic accuracy, and evidence-based IBD management 
• Collaborative knowledge transfer is based on German clinical experience and guidelines 
• In parallel, a structured research project has been initiated to:
• Evaluate diagnostic timelines in IBD patients in Azerbaijan 
• Identify system-level delays and bottlenecks 
• Analyze healthcare access barriers and diagnostic inefficiencies 
• Improve future patient pathways and outcomes 

Key Strength of INDID Telemedicine Approach

INDID Telemedicine integrates:

• Cross-border diagnostic confirmation and expert review 
• Multidisciplinary IBD management in German reference centers 
• Evidence-based therapeutic decision-making 
• Continuous medical education and capacity building in partner countries 
• Structured long-term remote follow-up and disease monitoring 

This model aims to reduce diagnostic delays, improve treatment accuracy, and strengthen local healthcare systems through sustained international collaboration.

References

1. Torres, J., et al. (2020). ECCO Guidelines on Therapeutics in Crohn’s Disease and Ulcerative Colitis. Journal of Crohn’s and Colitis. 
2. Feuerstein, J. D., et al. (2023). ACG Clinical Guidelines: Management of Inflammatory Bowel Disease. American Journal of Gastroenterology. 

Levine, A., et al. (2021). Pediatric and Adult IBD: Treat-to-Target Strategy. Gastroenterology.